Table 2.
Adjusted total, pre-, and post-transplant hospitalization costs based on MCS strategy
| Total Hospitalization Costs | N (%) | Adjusted Costs ¥ | p-value § | |||
|---|---|---|---|---|---|---|
|
|
||||||
| All patients | 2873 | (100%) | $509,870 | ($374,529 - | $752,899) | - |
| Type of MCS | ||||||
| None | 2268 | (78.9%) | $457,086 | ($347,270 - | $644,527) | <0.001 |
| VAD | 470 | (16.4%) | $755,345 | ($580,149 - | $1,059,854) | Ref. |
| ECMO | 135 | (4.7%) | $808,771 | ($572,341 - | $1,157,392) | 0.292 |
|
| ||||||
| Pre-Transplant Costs | N (%) | Adjusted Costs ¥ | p-value | |||
|
|
||||||
| All patients | 2873 | (100%) | $163,718 | ($79,772 - | $307,702) | - |
| Type of MCS | ||||||
| None | 2268 | (78.9%) | $124,019 | ($65,758 - | $222,382) | <0.001 |
| VAD | 470 | (16.4%) | $420,636 | ($307,741 - | $628,794) | Ref. |
| ECMO | 135 | (4.7%) | $252,497 | ($161,216 - | $446,178) | <0.001 |
|
| ||||||
| Post-Transplant Costs | N (%) | Adjusted Costs ¥ | p-value | |||
|
|
||||||
| All patients | 2873 | (100%) | $330,631 | ($262,561 - | $448,521) | - |
| Type of MCS | ||||||
| None | 2268 | (78.9%) | $324,887 | ($258,402 - | $434,268) | 0.588 |
| VAD | 470 | (16.4%) | $329,198 | ($264,426 - | $442,113) | Ref. |
| ECMO | 135 | (4.7%) | $540,540 | ($391,916 - | $723,485) | <0.001 |
§
P-values from the Wilcoxon rank sum test comparing VAD vs. no support and VAD vs. ECMO
¥
Cost model adjusted for the following variables: Patient age, diagnosis, race, blood type, hospital, ECMO (pre- or post-transplant), VAD, ventilator support, inotropic support, length of ICU stay post-transplant, dialysis post-transplant, and transplant year.